Helixmith Co., Ltd (KOSDAQ:084990)
South Korea · Delayed Price · Currency is KRW 3,060.00
-40.00 (-1.29%)
Sep 1, 2026, 3:30 PM KST
Helixmith Revenue
Helixmith had revenue of 554.94M KRW in the quarter ending March 31, 2026, a decrease of -40.36%. This brings the company's revenue in the last twelve months to 2.22B, down -56.31% year-over-year. In the year 2025, Helixmith had annual revenue of 2.60B, down -47.77%.
Revenue (ttm)
2.22B
Revenue Growth
-56.31%
P/S Ratio
64.22
Revenue / Employee
58.49M
Employees
38
Market Cap
142.75B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.60B | -2.38B | -47.77% |
| Dec 31, 2024 | 4.97B | 772.35M | 18.38% |
| Dec 31, 2023 | 4.20B | 1.40B | 50.08% |
| Dec 31, 2022 | 2.80B | 483.36M | 20.87% |
| Dec 31, 2021 | 2.32B | -1.93B | -45.48% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bioneer | 338.01B |
| GC Cell | 162.00B |
| HLB Therapeutics | 64.45B |
| GC Genome | 32.64B |
| Prestige BioPharma | 16.21B |
| Anterogen.Co.,Ltd. | 8.37B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.74B |
Helixmith News
- 10 months ago - A Look Into Vipshop Holdings Inc's Price Over Earnings - Benzinga
- 1 year ago - P/E Ratio Insights for Vipshop Holdings - Benzinga
- 2 years ago - Price Over Earnings Overview: Vipshop Holdings - Benzinga